Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.56 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16046772 | 0.86 | PDE10A (0.56) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL16044521 | 0.83 | PDE10A (0.56) | PDE10ACYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL10686237 | 0.82 | PDE10A (0.68) | PDE10ACYSLTR1CYSLTR2GPBAR1CYP1A2 | |
| SCHEMBL8799759 | 0.81 | CYSLTR1 (0.57) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL8800062 | 0.81 | PDE10A (0.54) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL810027 | 0.80 | TLR4 (0.53) | — | |
| SCHEMBL2567854 | 0.80 | LMNA (0.69) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL5779125 | 0.79 | CYSLTR1 (0.62) | PDE10ACYSLTR1CYSLTR2GPBAR1ALOX5 | |
| SCHEMBL2566156 | 0.79 | PDE10A (0.57) | PDE10ACYP1A2 | |
| SCHEMBL10512475 | 0.77 | PDE10A (0.77) | PDE10ACYSLTR1CYSLTR2GPBAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-101443334-A | Anti-viral compounds | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PDE10A 4218/4885CYSLTR1 4364/4885CYSLTR2 4514/4885 |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PDE10A 4218/4885CYSLTR1 4364/4885CYSLTR2 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.